Tobam Sells 4,022 Shares of The Clorox Company (NYSE:CLX)

Tobam cut its position in The Clorox Company (NYSE:CLX - Free Report) by 8.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,736 shares of the company's stock after selling 4,022 shares during the period. Clorox accounts for about 2.6% of Tobam's investment portfolio, making the stock its 8th biggest position. Tobam's holdings in Clorox were worth $6,146,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Clorox by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 15,507,152 shares of the company's stock worth $2,518,517,000 after purchasing an additional 124,428 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Clorox by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company's stock worth $501,925,000 after acquiring an additional 69,969 shares during the last quarter. Stifel Financial Corp raised its position in shares of Clorox by 0.4% during the fourth quarter. Stifel Financial Corp now owns 2,344,408 shares of the company's stock worth $380,761,000 after acquiring an additional 9,582 shares during the last quarter. Norges Bank bought a new position in Clorox in the fourth quarter valued at about $259,041,000. Finally, Northern Trust Corp increased its position in Clorox by 18.2% in the fourth quarter. Northern Trust Corp now owns 1,494,265 shares of the company's stock worth $242,684,000 after purchasing an additional 230,173 shares during the period. 78.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on CLX shares. Barclays reduced their target price on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research note on Wednesday, May 7th. Evercore ISI set a $140.00 price objective on shares of Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Morgan Stanley dropped their target price on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price target on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Finally, Citigroup dropped their price objective on Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a report on Monday, April 14th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, Clorox currently has an average rating of "Hold" and a consensus price target of $151.23.

Insiders Place Their Bets

In related news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.57% of the company's stock.

Clorox Stock Down 3.3%

Shares of CLX traded down $4.25 on Friday, hitting $123.03. The company's stock had a trading volume of 1,709,082 shares, compared to its average volume of 1,358,799. The firm's fifty day moving average price is $135.18 and its 200-day moving average price is $148.78. The Clorox Company has a fifty-two week low of $122.87 and a fifty-two week high of $171.37. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The firm has a market capitalization of $15.16 billion, a price-to-earnings ratio of 33.61, a P/E/G ratio of 2.62 and a beta of 0.54.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The company's revenue was down 8.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.71 earnings per share. On average, equities research analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.